Saturday, Pfizer Announced Detailed Overall Survival Results From Phase 3 ECHELON-3 Study Of Adcetris Plus Lenalidomide And Rituximab For Relapsed/Refractory Diffuse Large B-cell Lymphoma, Showing Adcetris Combo Reduced Risk Of Death By 37% Vs. Placebo
Portfolio Pulse from Benzinga Newsdesk
Pfizer announced detailed results from the Phase 3 ECHELON-3 study, showing that the combination of Adcetris, Lenalidomide, and Rituximab significantly reduced the risk of death by 37% compared to placebo in patients with relapsed/refractory diffuse large B-cell lymphoma.
June 03, 2024 | 9:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer's Phase 3 ECHELON-3 study results show a significant reduction in the risk of death for patients with relapsed/refractory diffuse large B-cell lymphoma using the Adcetris combination therapy.
The positive results from the Phase 3 ECHELON-3 study are likely to boost investor confidence in Pfizer's oncology portfolio, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100